| scholarly article | Q13442814 |
| P356 | DOI | 10.1159/000334340 |
| P953 | full work available online at | https://www.karger.com/Article/Pdf/334340 |
| P698 | PubMed publication ID | 22286903 |
| P2093 | author name string | Hyun-Soo Kim | |
| Gou Young Kim | |||
| Sung-Jig Lim | |||
| Youn Wha Kim | |||
| P2860 | cites work | Activation status of receptor tyrosine kinase downstream pathways in primary lung adenocarcinoma with reference of KRAS and EGFR mutations | Q43179588 |
| PTEN expression in breast and endometrial cancer: correlations with steroid hormone receptor status | Q43901794 | ||
| Rapamycin inhibits the growth and metastatic progression of non-small cell lung cancer | Q44735709 | ||
| Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions | Q44968631 | ||
| Critical and diverse involvement of Akt/mammalian target of rapamycin signaling in human lung carcinomas | Q46194088 | ||
| Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. | Q46708758 | ||
| Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis | Q47680928 | ||
| PTEN mutations in gliomas and glioneuronal tumors. | Q47995275 | ||
| Higher pAkt expression predicts a significant worse prognosis in glioblastomas | Q48228324 | ||
| Prognostic and predictive values of pERK1/2 and pAkt-1 expression in non-small cell lung cancer patients treated with adjuvant chemotherapy. | Q54632156 | ||
| The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate | Q24317714 | ||
| Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. | Q27824772 | ||
| TOR signaling in growth and metabolism | Q27860757 | ||
| Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers | Q28145813 | ||
| International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma | Q28303718 | ||
| mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt | Q29547767 | ||
| PTEN induces apoptosis and cell cycle arrest through phosphoinositol-3-kinase/Akt-dependent and -independent pathways | Q31837554 | ||
| Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors | Q33385120 | ||
| Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors | Q34010378 | ||
| mTOR-targeted therapy of cancer with rapamycin derivatives | Q34397003 | ||
| Prognostic effect of epidermal growth factor receptor gene mutations and the aberrant phosphorylation of Akt and ERK in ovarian cancer | Q34616626 | ||
| Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast | Q35788322 | ||
| Targeting the molecular target of rapamycin (mTOR). | Q35997230 | ||
| mTOR and cancer: reason for dancing at the crossroads? | Q36344439 | ||
| Cancer statistics in Korea: incidence, mortality and survival in 2005. | Q37418027 | ||
| Activation of the mTOR signaling pathway in breast cancer and its correlation with the clinicopathologic variables | Q38504589 | ||
| Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors | Q40205287 | ||
| Significance of Akt phosphorylation on tumor growth and vascular endothelial growth factor expression in human gastric carcinoma | Q40265342 | ||
| Determinants of rapamycin sensitivity in breast cancer cells | Q40590648 | ||
| mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer | Q42660087 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | sirolimus | Q32089 |
| adenocarcinoma | Q356033 | ||
| P304 | page(s) | 84-93 | |
| P577 | publication date | 2012-01-27 | |
| P1433 | published in | Pathobiology | Q2948036 |
| P1476 | title | Expression of the Mammalian Target of Rapamycin Pathway Markers in Lung Adenocarcinoma and Squamous Cell Carcinoma | |
| P478 | volume | 79 |
| Q49181173 | Down-regulation of Claudin-2 Expression and Proliferation by Epigenetic Inhibitors in Human Lung Adenocarcinoma A549 Cells |
| Q33633647 | Loss of phosphatase and tensin homolog expression correlates with clinicopathological features of non-small cell lung cancer patients and its impact on survival: A systematic review and meta-analysis |
| Q83974502 | Reduced N-Myc downstream-regulated gene 2 expression is associated with CD24 upregulation and poor prognosis in patients with lung adenocarcinoma |
| Q53226241 | Sirolimus use and cancer incidence among US kidney transplant recipients |
| Q64269604 | The Prognostic Role of Ribosomal Protein S6 Kinase 1 Pathway in Patients With Solid Tumors: A Meta-Analysis |
Search more.